Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruption and those under immunosuppressive therapy

DOI Web Site Web Site PubMed 被引用文献16件 参考文献121件 オープンアクセス
  • Shiohara Tetsuo
    Department of Dermatology, Kyorin University School of Medicine
  • Kurata Maiko
    Department of Dermatology, Kyorin University School of Medicine
  • Mizukawa Yoshiko
    Department of Dermatology, Kyorin University School of Medicine
  • Kano Yoko
    Department of Dermatology, Kyorin University School of Medicine

書誌事項

タイトル別名
  • Recognition of Immune Reconstitution Syndrome Necessary for Better Management of Patients with Severe Drug Eruptions and Those under Immunosuppressive Therapy
  • Recognition of immune reconstitution syndrome necessary for better manage of patients with severe drug eruptions and those under immunosuppressive therapy

この論文をさがす

説明

The immune reconstitution syndrome (IRS) is an increasingly recognized disease concept and is observed with a broad-spectrum of immunosuppressive therapy-related opportunistic infectious diseases and severe drug eruptions complicated by viral reactivations. Clinical illness consistent with IRS includes tuberculosis, herpes zoster, herpes simples, cytomegalovirus infections and sarcoidosis: thus, the manifestations of this syndrome and diverse and depend on the tissue burden of the preexisting infectious agents during the immunosuppressive state, the nature of the immune system being restored, and underlying diseases of the hosts. Although IRS has originally been reported to occur in the setting of HIV infection, it has become clear that the development of IRS can also be in HIV-negative hosts receiving immunosuppressive agents, such as prednisolone and tumor necrosis factor α inhibitors, upon their reduction and withdrawal. Drug-induced hypersensitivity syndrome, a life-threatening multiorgan system reaction, is another manifestation of the newly observed IRS. Clinical recognition of the IRS is especially important in improving the outcome for diseases with an otherwise life-threatening progenosis. Clinicians should be aware of the implications of IRS and recognize that relieving the symptoms and signs of immune recovery by anti-inflammatory therapies needs to be balanced with anti-microbial therapies aiming at reducing the amplitude and duration of tissue burden of preexisting microbes.<br>

収録刊行物

被引用文献 (16)*注記

もっと見る

参考文献 (121)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ